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Abstract Patient acceptability of a medicinal product is a
key aspect in the development and prescribing of medi-
cines. Children and older adults differ in many aspects
from the other age subsets of population and require par-
ticular considerations in medication acceptability. This
review highlights the similarities and differences in these
two age groups in relation to factors affecting acceptability
of medicines. New and conventional formulations of
medicines are considered regarding their appropriateness
for use in children and older people. Aspects of a formu-
lation that impact acceptability in these patient groups are
discussed, including, for example, taste/smell/viscosity of a
liquid and size/shape of a tablet. A better understanding of
the acceptability of existing formulations highlights
opportunities for the development of new and more
acceptable medicines and facilitates safe and effective
prescribing for the young and older populations.
Key Points
Appropriate pharmaceutical design of oral medicines
can improve acceptability and patient outcomes in
paediatric and geriatric populations.
Similar considerations should be given to physical
characteristics affecting swallowability of tablets and
capsules for use in children and older patients.
Whilst formulation factors such as taste and smell
are important features for paediatric medicines, safe
swallowing is the key formulation factor in
designing medicines for older patients.
1 Introduction
Acceptability has previously been defined as ‘‘an overall
ability of the patient and caregiver (defined as ‘user’) to use
a medicinal product as intended (or authorised)’’ [1]. This
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terminology is used as the basis for this review article.
Additional consideration is required in developing medi-
cines for young and older patients as their physiological and
cognitive responses may differ due to the developing and
deteriorating conditions of the body, respectively. Oral
administration is the most common route of drug delivery to
both young and older patients. However, there are obstacles
for young and older patients to accept their oral medicines,
e.g. swallowing difficulties or dysphagia, the involvement
of caregivers, child recalcitrance and polypharmacy in the
older population, to name just a few. While these barriers
may not be considered major issues for adults, they could
potentially affect adherence in young and older patients. In
many cases, oral medicines are modified to ease adminis-
tration in these patients, ranging from simple removal from
packaging to dispensing in a dosette box, to more complex
alterations including crushing or splitting of solid oral
dosage forms [2–6]. Altering medication dosage forms,
whether for children or adults, leads to unlicensed use of
medicines and can potentially change bioavailability, tox-
icity and stability of the medicines.
Guidance issued by the European Medicines Agency
(EMA) highlighted that acceptability must be an integral
part of paediatric formulation development [7]. Recently,
the EMA Geriatric Expert Group has issued a concept
paper on the need for a reflection paper on the quality
requirements of medicines for older adults [8]. The EMA
Quality Working Party is currently looking into drafting
the reflection paper. Similar principles might apply to
assess the acceptability of medicines in children and older
adults; however, a duplicate approach might not be
appropriate due to the different patient-centred issues in
these two populations. The aim of this review is to high-
light the similarities and differences between children and
older adults in relation to the acceptability of oral medi-
cines. A detailed analysis of barriers associated with
administration of oral medicines guides the choice and
development of appropriate medicines to meet the needs of
both patient groups (see the Electronic Supplementary
Material for a description of the search strategy).
2 Patient-Centred Factors Affecting Acceptability
of Oral Medicines
Table 1 summarises the most important patient-related
factors that affect oral medication acceptability in children
and older adults.
2.1 Patient Characteristics
There is no such thing as a standard paediatric or geriatric
patient. As the physiological and cognitive systems
continue to develop or be impaired, chronological age is
not the best indicator to predict the characteristics of the
patient. Frailty does not always accompany very old age
nor do all infants mature at the same rate. The heteroge-
neity is higher in the older adult group as the definition and
recognition of the physiological changes with advanced
age is diverse.
2.2 Drug Therapy-Associated Factors
The duration of treatment and the required number of
medicines potentially increase the complexity of accep-
tance to medicines in older adults. Many older adults are on
multiple medications to treat their multi-morbidities [9].
The dose regimen further complicates adherence and
acceptance of medicines [10]. In this respect, multi-com-
partment adherence aids are promising in terms of helping
patients to remember to take their medicines at the right
time [11].
2.3 Socio-Cultural Factors
In both populations the involvement of a caregiver is
common; therefore, there is a need for the directions on
usage of a medicine to be clear both to the patient and the
caregiver. Older adults living in their own home may be the
sole person responsible for their medicine management,
whereas seniors living in nursing homes are often helped
by formal carers or by nurses at hospitals. The majority of
paediatric populations, except adolescents, are typically
dependent on their parents/carers to take their medicines.
As such, the ability and willingness of the carer to
administer a medicine to these patients as intended could
determine the acceptability of the medicine and outcome of
the treatment [12–16].
The acceptability of medicines may be influenced by the
setting in which the administration of the medicine takes
place. Children with minor diseases may need to take
medications during nursery/school hours. Chronically ill
children may need to take their regular medicines or
medicines for the treatment of acute problems at school.
Peer pressure and child recalcitrance are potential factors
affecting their acceptance of a medication form in these
cases.
2.4 Dysphagia in Children and Older Adults
The ability to swallow determines the acceptability of
conventional medication forms such as tablets and cap-
sules. Swallowing is a rapid, albeit complex, process that
involves two essential actions: bolus transport and airway
protection. The process of deglutition is generally divided
into three main phases: the oral phase, the pharyngeal
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phase and the oesophageal phase. Dysphagia is defined as
difficulty in swallowing and can occur in both children and
older adults [18]. While swallowing reflexes can be
observed as early as in utero, significant maturation related
to deglutition occurs between 6 months and 3 years of age,
with complete maturation generally believed to have
occurred by 6 years of age [19, 20].
The prevalence of paediatric dysphagia is difficult to
ascertain given the wide variations in how swallowing
impairments are defined and the assessment measures used
to identify them. The causes of paediatric dysphagia can be
medical, developmental, behavioural, psychological, or it
may indeed be a multidimensional disorder. Common aeti-
ologies include prematurity, developmental disorders, neu-
rological disorders, reflux and craniofacial abnormalities
[21, 22]. Although the exact incidence of dysphagia is
unknown, it is reportedly becoming more common given the
improved prognosis of pre-mature infants and of children
with chronic medical conditions [23, 24]. Nevertheless, it
has been reported that as many as 25–45 % of typically
developing children and up to 80 % of children with
developmental disabilities exhibit some form of feeding
disorders [21].
In contrast to children, the natural process of aging is
associated with a decline in swallowing function affecting
all three phases of deglutition [25]. Poor dentition and
reduction in masticatory strength in older age are the main
causes of increases in oral-phase duration and the amount
of oral residue during swallowing. Age-related neuro-
muscular decline contributes to a delay in triggering
pharyngeal swallowing reflex and decreases in bolus
movement and clearance in the oesophageal phase. It was
estimated that 70–90 % of the older population experience
some degree of dysphagia [26]. In one study, 87 % of
residents in a care home (average age of 87 years)
reported mealtime difficulties related to swallowing and
68 % showed signs of dysphagia [27]. The prevalence of
dysphagia is particularly high in patients with age-related
Table 1 The most important patient-related factors affecting acceptability of oral medications in children and older adults
Factors Children Older adults
Patient characteristics
Age 0–18 years; divided into subgroups according to age [17].
A patient’s cognitive development should also be
considered in acceptability of medicines
[65 years; age alone is not the only determinant affecting
patients’ health conditions and ability to take
medicines; frailty could be more important than age
Health conditions A single condition is more common than the presence of
co-morbidities in paediatric populations
Co-morbidities are common; medication handling and
administration can be affected by many diseases that
are highly prevalent such as dementia, Parkinson’s
disease, head and neck cancer, and stroke, and common
functional conditions, e.g. visual and cognitive
impairments and neuromuscular degeneration
Disease status Acute conditions and long-term illnesses are both present
although acute conditions are more common
Acute conditions and long-term illnesses are both present
although chronic conditions are more common
Ability to swallow Very young children may have difficulties swallowing
conventional tablets and capsules
Dysphagia is common and affects ability to take oral
medicines; many age-related conditions can cause
swallowing difficulties
Drug therapy-associated factors
Duration of therapy Short- and long-term treatments are both required
although short-term treatments are more common
Long-term treatments are common; acceptability to
medicines can be affected by treatment outcomes of
long-term therapy
Concomitant
medications
A single medication for the treatment of a single disease
is more common than multiple medications due to the
prevalence of acute rather than chronic illness
Polypharmacy (taking more than 5 medicines at the same
time) has high prevalence; the number of medicines
taken can affect the preference of dosage forms, e.g.
patients taking numerous tablets may prefer fixed-dose
combinations
Social factors
Responsibility for
medication
administration
Young children are usually helped by caregivers; older
children can self-administer medicines
Independent-living older adults can self-administer
medicines; in other cases they can be helped by
caregivers
Caregivers Usually adults including parents/guardians, nursery
practitioners and school teachers
A mixture of different characteristics; could be older-age
partners or nursing home/hospital nurses
Environments where
oral medication
administration occurs
Home, nursery, school, hospital Home, residential home, nursing home, hospital
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diseases such as Parkinson’s disease (80 %), Alzheimer’s
disease (40–70 %) and acute stroke (50 %) [28–31].
3 Factors Affecting Acceptability of Tablets
and Capsules
3.1 Acceptability of Tablets and Capsules in Children
The age at which most children acquire the skills to
swallow tablets and capsules safely has been the subject of
much debate. Early literature widely quotes 6 years as a
general age from which these dosage forms may be con-
sidered suitable for children [32]. Recent evidence suggests
that some children may have already acquired the ability to
swallow tablets and capsules from an earlier age, or in
some cases can be taught using behavioural training
interventions. For example, Yeung and Wong [33] found
that children with HIV as young as 3 years were prescribed
stavudine as a solid dosage form. In a recent study in
Uganda and Zimbabwe, 36 % of children were able to
swallow antiretroviral tablets intact (mean age 3.3 years),
while 64 % required them to be crushed or dispersed (mean
age 2.9 years) [34]. Behavioural techniques to aid swal-
lowing of both tablets and capsules involving children as
young as 2–3 years old have also been described; however,
such reports are limited to specific diseases and small
sample sizes [35–41].
Although swallowing ability may be perceived to
improve with age, some studies have reported swallowing
difficulties in adolescence. In a general paediatric clinic in
Denmark, nearly half (43 %) of parents surveyed reported
children aged 12 years and younger experienced difficul-
ties taking both liquids and tablets, primarily due to taste
and swallowability; problems in administering tablets were
more pronounced [42]. In a qualitative study, Hansen et al.
[43] found that more than one-third of adolescents descri-
bed difficulties in taking oral medications, particularly
swallowing tablets, primarily due to taste and size. Polaha
et al. [44] similarly reported that around one-third of
children and adolescents had refused and rejected tablets at
least once; interestingly, frequent medication users were
more likely to refuse them despite reportedly having better
tablet swallowing skills. Difficulties in swallowing have
nonetheless been implicated as a barrier to adherence in
children in various chronic conditions [38, 45–47].
The ability to swallow tablets and capsules is one of the
factors that influence the age at which children convert
from liquid to solid formulations. Following analysis of
community prescription data in Netherlands, Schirm et al.
[48] found that the use of tablets and capsules exceeded
liquids from the age of 7 years for licensed products,
3 years for off-label medicines and 9 years for unlicensed,
pharmacy-compounded medicines. Similarly, in the UK,
the average age of conversion from liquid to solid anti-
retroviral formulations was 7.3 years [33]. It is worth
noting that many factors can potentially affect this con-
version age, e.g. the availability of tablets of the right size
and strength for paediatric use and the acceptance of pre-
scribing an unlicensed medicine when an authorised for-
mulation is available. Comparison of the practice in
different countries would be an interesting topic for future
study.
The ability of children to swallow tablets and capsules is
strongly related to the size of these dosage forms, alongside
age. However, current guidance on the suitability of tablet
sizes for different age groups in children is based upon
anecdotal feedback and perception [7]. Direct evidence in
this area is scarce and future research in this area is
required. Table 2 summarises the published evidence on
the ability of children to swallow tablets of different
dimensions based upon age. Mini-tablets (1–4 mm in
diameter) are relatively new dosage forms with consider-
able promise in paediatrics [17, 49]. Mini-tablets can be
administered directly (swallowed whole) or could be
labelled for sprinkling onto food. Various research studies
have recently assessed the acceptability of mini-tablets in
infants and children (Table 2). While these exploratory
studies demonstrate their proof of concept, each involved
administration of single mini-tablets, whereas multiple
mini-tablets are more likely to be used clinically to provide
the appropriate dose. Further research is required to dem-
onstrate the application of mini-tablets in practice.
3.2 Acceptability of Tablets and Capsules in Older
Patients
In older patients, age- or disease-related swallowing diffi-
culties affect their ability to take solid oral medicines. In a
survey involving 17 community pharmacies from England
and Northern Ireland, 60 % of patients aged between 60
and 89 years experienced difficulties in swallowing tablets
and capsules [56]. A recent study reported that 37.4 % of
adult patients (mean age 62 years) attending their general
practices had difficulties in swallowing medicines [57].
Polypharmacy (taking C5 medicines) is common in older
patients [9]. A study conducted in Switzerland showed that
community-dwelling polypharmacy patients (mean age
67 years) reported ongoing (9.0 %) or past (13.4 %)
swallowing difficulties that resulted in intentional non-
adherence in 23 % of these patients [58].
Anxiety, previous bad experiences and disliking the idea
of taking medicines could all contribute to difficulties for
older patients in taking tablets and capsules [57]. Effortful
swallowing, a process of swallowing ‘hard’ using oral and
pharyngeal muscles, is commonly advised by speech and
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language therapists to help dysphagia patients and could
increase the oral swallowing pressure to propel the swal-
lowed object more effectively [59]. It was shown that
targeted training using swallow-related exercises signifi-
cantly improved swallowing performance of patients with
Parkinson’s disease [60]. Indeed, some patients with dys-
phagia found that concentrating on swallowing improved
their ability to swallow solid dosage forms [61].
3.3 Factors Affecting Swallowability and Oesophageal
Transit of Tablets and Capsules in Adults
During the swallow process, there is a risk for tablets and
capsules to adhere to the oesophagus, causing prolonged or
incomplete oesophageal transit. A trapped dosage form can
start to disintegrate or dissolve within the oesophagus and
cause oesophageal injury, often due to altered local pH or
hyper-osmolarity [62]. The swallowability and oesopha-
geal transit of tablets and capsules are affected by many
physical characteristics of the dosage form. However, lit-
erature reports on swallowability of tablets and capsules
were typically conducted in the adult population and data
from children and older adults are scarce. Difficulties in
swallowing and oesophageal retention of tablets and cap-
sules are expected to be magnified in children and older
adults; therefore, the findings of studies in adults provide
useful guidance. Nevertheless, studies that are directly
conducted in paediatric and geriatric populations would be
valuable to guide the design of medicines for these
patients.
Tablet size was found to affect the swallowability and
oesophageal transit in adults; smaller tablets were consid-
ered easier to swallow and showed faster oesophageal
transit than larger tablets (Table 3). Shape, density, surface
characteristics and type of formulation can all affect the
swallowability and oesophageal transit of tablets and cap-
sules (Table 3). Visual aspects of medicines such as colour
can be adapted not only to provide an aesthetic dosage
form that is acceptable to patients, but to aid users in
recognising and differentiating medicines. The colour of
tablets is associated with flavour perceptions and there are
many reviews on the topic [63]. Tablet colour has been
linked with taste, where pink is considered to be sweeter
than red, and yellow is considered to be salty irrespective
of its actual ingredients [64]. The colour of a medication
has also been connected with specific ailments and can
affect patient adherence. A change in tablet colour was
associated with non-adherence in adult patients with epi-
lepsy [65]. There have been reviews on the effect of colour
of tablets and perceptions of efficacy [66]. Colour prefer-
ences among children have shown to be stereotypically
gender dependent [67], and they seem to prefer brightly
coloured medicines. In older patients, white was seen as the
most popular colour choice for tablets; however, those
patients who take more than ten tablets every day prefer
brighter colours than patients who take fewer tablets [68].
Table 2 Literature reports on the ability of children to swallow tablets in relation to age and tablet size
Age of
children
Sample
size
Tablet size Study outcomes References
1–9 years 555 7 mm ketoprofen
tablets
80 % of parents reported that their children had no problems with swallowing,
although administration problems were three times more common in those
under 2 years of age than in older children
[50]
2–11 years 96 5 and 8 mm 1–7 tablets were taken by children over several months. No reports of
swallowing difficulties or adverse events
[51]
6–11 years 113 7 mm 91 % of children aged 6–11 years were able to swallow the tablet; 46 % without
training, 38 % trained with an ordinary plastic cup and 7 % with the assistance
of a patented pill cup
[41]
2–6 years 100 3 mm mini-tablets 46 % of 2-year-olds and 87 % of 5-year-olds were able to swallow a single
mini-tablet
[52]
From
6 months
306 2 mm coated and
uncoated mini-
tablets
Children as young as 6 months old were capable of swallowing the mini-tablets,
with acceptability of the mini-tablets superior to 3 mL glucose syrup. Some
instances of chewing before deglutition were observed across the various age
groups, with around half of children aged 1–3 years swallowing the mini-
tablets intact. Two incidences of coughing were reported for coated mini-
tablets, both in children below 1 year of age
[53]
6–30 months 16 2 mm enteric-coated
pancrelipase
mini-tablets
The mini-tablets were administered with applesauce to the children. Ease of
swallowing was rated by parents on a 4-point scale (with 0 corresponding to
poor and 3 as excellent). The mean score of the mini-tablets was 1 (fair) to 2
(good)
[54]
1–4 years 183 4 mm uncoated
mini-tablets
The mini-tablets were significantly better accepted than 3 other dosage forms
(a powder, suspension and syrup)
[55]
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The ability of a patient to swallow tablets and capsules
is also affected by patient-related factors. The retention of a
tablet or capsule in the oesophagus is affected by the body
position of the patient while taking the medicine and the
volume of fluid taken with the medication (Table 3). It was
recommended that medications should be taken with at
Table 3 Factors affecting swallowability and oesophageal transit of tablets and capsules
Study population Outcome measure Summary of outcomes References
Tablet size
Male adults aged 24–33 years Ease of swallowing Swallowing larger tablets required significantly more swallows
and more effort in swallowing than smaller tablets
[73]
Adults (age range 17–82 years) Oesophageal transit Smaller tablets have shown faster oesophageal transit than
larger tablets
[69, 74, 75]
Adults (age range 23–77 years) Oesophageal transit Large tablets (11 mm) showed significantly longer oesophageal
transition time than small (5.5 mm) and medium (8 mm) size
tablets
[69]
Older adults (aged 59–80 years) Oesophageal transit Oesophageal transit of tablets as small as 4 mm in diameter can
be prolonged
[76]
Tablet shape
84 % participants aged
23–64 years and 15 % aged
65 years or older
Ease of swallowing Arched (curved), oval and oblong tablets were generally easier
to swallow than flat round tablets. Oblong tablets were
considered difficult to swallow for small tablets
[68]
Male adults aged 24–33 years Ease of swallowing Medium or large tablets were preferred to be oblong or oval,
while small round tablets were considered as easy to swallow
as other shapes
[73]
Adults (age range 17–82 years) Oesophageal transit Oval tablets were easier to pass through the oesophagus than
round tablets, especially when the tablet is large
[69, 74]
Film coating
Male adults aged 24–33 years Ease of swallowing A film coating applied to the surface of the tablet was found to
make swallowing easier
[73]
Adults (age range 17–82 years) Oesophageal transit Film coatings improve oesophageal transit of both large and
small tablets compared to uncoated tablets
[69, 74]
Density
Adults (age range 17–82 years) Oesophageal transit Heavy large capsules passed through the oesophagus
significantly faster than light large capsules in a standing
position
[74]
Type of formulation
Older adults (mean age 66, range
50–79 years)
Oesophageal transit The oesophageal transit time of gelatine capsules was
significantly longer than enteric-coated and cellulose-based
film-coated tablets
[77, 78]
Adults (age not specified) Oesophageal transit Barium sulphate tablets were more likely to stick to the
oesophagus than capsules of the same drug
[79]
Adults (age range 17–82 years) Oesophageal transit Large capsules passed through the oesophagus significantly
faster than uncoated oval tablets and their transit was less
affected by the posture of the patient than tablets
[74]
Adults (age range 19–80 years) Oesophageal transit Oesophageal passage of capsules was not affected either by
capsule size or the amount of water taken at the same time,
both of which had significant influence on the transit of tablets
[69]
Body position of the patient
Adults (age range 17–82 years) Oesophageal transit Oesophageal transit of tablets and capsules are significantly
faster in patients in the standing position than in the supine
position
[69, 74, 75, 80, 81]
Fluid taken
Adults (age range 17–82 years) Oesophageal transit Tablets and capsules pass through the oesophagus faster when a
large quantity of fluid is taken with the medication
[80–82]
Adults (age range 19–80 years) Oesophageal transit The most common cause of oesophageal retention of tablets and
capsules was the combination of a small volume of water
(25 mL) and the supine position. When a large quantity of
water (100 mL) was taken, the transit time was significantly
shorter for small and large tablets in the supine position and
for large tablets in the standing position
[69]
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least 100 mL of fluid and the patient remains standing for
at least 90 s to prevent oesophageal retention [69].
Although useful guidance, some older patients may not be
able to follow this advice, as they may be bedridden or may
have difficulty in swallowing a large amount of fluid [70].
Similarly, this volume may be too large for children to
take.
3.4 New ‘Easy-to-Swallow’ Technologies to Aid
in Swallowability of Tablets and Capsules
Several technologies have been developed to aid the
swallowing of solid oral dosage forms. A disposable device
called MedCoat (Med Coat AB, Stockholm, Sweden) can
be used by the patient to apply a thin coat on the tablet
before swallowing [71]. The coating contains gelatine,
sweeteners and flavouring agents and can improve the taste
of the tablet. In a clinical trial (average age 30 years), the
coating improved the ease of swallowing of tablets, espe-
cially bitter-flavoured placebo tablets [71]. A similar fla-
voured spray product Pill Glide (FLAVORx Inc.,
Columbia, MD, USA) requires the patient to apply the
spray to the back of the mouth and tongue before taking
tablets or capsules [72]. The spray creates a lubricated
surface in the mouth and thus facilitates swallowing. Pill
Glide has been found to be helpful in adolescents with
difficulties in swallowing tablets.
4 Factors Affecting Acceptability of Oral Liquid
Dosage Forms
Oral liquids are generally regarded to be the most appro-
priate dosage form for children despite having issues
including taste masking, portability, stability and the
inclusion of excipients that are not always appropriate for
all paediatric patients. The challenge in using liquid for-
mulations in older patients, particularly those with dys-
phagia, is aspiration, which is caused by inadequate
protection of the airway during swallowing. The preva-
lence of aspiration was reported as 51 % in dysphagia
patients and 36 % of healthy older adults showed some
degree of aspiration during normal swallowing [83, 84].
Patient acceptability of a liquid dosage form is inevita-
bility affected by many of its characteristics (Table 4).
Modifications in these formulation factors can improve
swallowing of a liquid by moderating the timing and
response of oral, pharyngeal and oesophageal phases.
4.1 Taste, Smell and Palatability of a Liquid
Taste is regarded as the most important factor determining
the acceptability of a liquid medicine in children. There
have been several studies undertaken that investigated the
taste of liquid medicines in paediatric populations. These
typically use face-rating scoring systems to evaluate the
taste in this population and an example study was con-
ducted by Cohen et al. [108]. Review articles have been
published on this area and the reader is directed to the
review by Ernest et al. for additional information [109].
Research has linked smell of a liquid to flavour and it
has been argued that the majority of the flavour of food
actually comes from its smell [110]. It is likely that certain
medicines do smell unpleasant, yet there is very limited
work done in this area, particularly in linking medication
odour to compliance/adherence (Table 5).
The effect of taste on medication acceptability in older
patients has not been extensively investigated compared to
the paediatric population. However, the unpleasant taste of
liquid medicines was identified as one of the barriers for
older patients with dysphagia to taking their medications
[61]. Swallowing is modulated by the nervous inputs
generated from sensory receptors in the oral, pharyngeal
and laryngeal regions via trigeminal, glossopharyngeal and
vagus nerves [111]. Taste, thermal and chemical properties
of the ingested fluid act as stimuli of these nerves and are
known to affect swallowing activities (Table 4). However,
the effect of taste was likely to decrease in older adults due
to the reduced taste sensitivity in older individuals [112].
Beneficial effects of a sour bolus, consisting of 50 %
lemon juice and water, on the oropharyngeal swallowing in
patients with neurogenic dysphagia were reported by
Logemann et al. [87] (Table 4). It was suggested that the
sour taste acted as an ‘‘alerting’’ stimulus and enhanced or
altered the sensory input to the nervous system and thus
facilitated oropharyngeal swallowing in neurogenic dys-
phagia patients. The strong sour taste was deemed
unpleasant by most participants and changing the liquid
into a palatable sweet and sour taste did not significantly
improve swallowing [91]. It is the challenge for future
research to utilise the benefit of the sour taste and improve
the palatability in the design of oral liquid medicines to
promote safe swallowing in older dysphagic patients.
4.2 Texture and Viscosity of a Liquid
The texture and mouth feel of particles is acknowledged as
important in food products as it affects mastication and
overall taste sensation [113]. Grittiness of particles has
previously been linked to particles[12 lm [113]. Texture
effects on acceptability of liquid medicines have not been
extensively investigated (Table 4) and it is an important
subject for future research.
The consistency and rheology of the swallowed bolus
affect the safety of swallowing [114, 115]. In particular,
liquids and thin pastes initiate significantly different
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Table 4 Factors affecting the swallowability and acceptability of liquid medicines
Study population Outcome measures Summary of outcomes References
Taste
Healthy young adults Swallowing speed Sweet, sour and salty tastes reduced the swallowing speed and prolonged
oral and pharyngeal swallowing durations compared with neutral tastes
[85]
Healthy young adults Swallow physiology Sweet, sour and salty tastes generated stronger muscle contractions and
shorter activation onset times during swallowing than the no-taste
conditions
[86]
Older adults (aged
65–85 years)
Swallow physiology The effects of sweet, sour and salty tastes on swallow physiology reduced
in older adults
[86]
Patients with
neurogenic dysphagia
Oropharyngeal swallowing A sour bolus reduced the swallow onset time, shortened the pharyngeal
delay and transit time, and improved oropharyngeal swallow efficiency
[87]
Palatability
Healthy young adults Swallowing physiology Palatability of the ingested liquid had little effect on swallowing
physiology and performances
[88, 89]
Adults aged
23–71 years
Oral, pharyngeal and
oesophageal transit
No difference was found on the duration of oral, pharyngeal and
oesophageal phases of swallowing between an unpleasant bitter bolus
and a pleasant sweet bolus
[90]
Older patients with
neurogenic dysphagia
Swallowing performance A pleasant sweet–sour mixture did not significantly improve swallowing
performances compared with water
[91]
Oral stimuli
Patients with stroke
(aged 41–88 years)
Pharyngeal transit The combination of sour taste and cold stimuli was able to improve
pharyngeal transit time
[92]
Healthy young adults Swallow performance Carbonated water was able to improve swallowing performances [88, 93]
Adult patients with
neurogenic dysphagia
Pharyngeal transit and
aspiration risk
Carbonated water significantly improved pharyngeal transit and reduced
aspiration and penetration risk scores compared with non-carbonated
thin liquid
[94]
Smell
Adults 5-Point scale on smell (5
being most positive score)
The smell of different liquid corticosteroid products (prednisolone 1 mg/
mL; prednisolone sodium phosphate 1 mg/mL and dexamethasone
0.5 mg/5 mL) was measured. Dexamethasone scored most positively;
this may be attributed to the lower concentration, as the taste was not
scored more positively than prednisolone
[95]
Texture
Adults Effects on palatability The texture of liquids was included in a study on the palatability of liquid
anti-infectives with acknowledgement that texture can influence
palatability of a liquid, although there were no additional details on
what textures are acceptable or otherwise
[96]
Adults 5-Point scale on texture (5
being most positive score)
The texture of different liquid corticosteroid products (prednisolone
1 mg/mL; prednisolone sodium phosphate 1 mg/mL and
dexamethasone 0.5 mg/5 mL) was measured. Prednisolone sodium
phosphate 1 mg/mL was scored most positively; this may be due to the
higher solubility of the salt form making the particle size smaller within
the product
[95]
Children aged
1–4 years
Acceptability Syrup was more acceptable to children than a suspension using placebo
formulation and this is likely related to the taste or texture difference
between these formulations
[55]
Viscosity
Healthy young adults Oropharyngeal transit Increasing the viscosity of the liquid slowed the oropharyngeal transit of
the bolus
[97–100]
Patients with
Parkinson’s disease
Timing and safety of
swallow
Increasing the viscosity of the liquid slowed the oropharyngeal transit of
the bolus and reduced aspiration/penetration risk scores by preventing
the premature emptying from the mouth before the pharyngeal swallow
response
[100]
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muscle activities during swallowing compared with thick
pastes, which could be associated with a higher risk of
aspiration in dysphagia patients [98]. Thin liquids pose a
high risk of aspiration due to their lack of resistance to flow
and they usually arrive at the hypopharynx before the onset
of the pharyngeal swallow. Increasing the viscosity of the
liquid slows the oropharyngeal transit of the bolus and thus
prevents the premature emptying from the mouth before
the pharyngeal swallow response [97–99].
4.3 Volume of a Liquid Administered
Small volumes are normally better tolerated for prepara-
tions with known palatability issues, unless a more diluted
preparation may allow better taste masking. There are
issues in very small volumes of oral liquids for adminis-
tration in children; these are generally related to the
accuracy of dosing relative to the devices available [116].
Minimal volumes are normally used when dosing very
young children via enteral tubes to ensure that sufficient
nutrition can be administered in addition to medication.
The typical volume of medicine administered in a child is
expected to be swallowable in one unit; therefore, the
maximum volume should equate to the volume of a swal-
low. The volume of a swallow is reported to be 4.5 mL for
children from 15 months to 3.5 years of age and this
equates to a typical volume of 0.27 mL/kg [117].
The volume of the liquid to be swallowed can affect the
safety of swallowing in older adults. A normal sip size for
healthy adults has been reported to be in the range of
17–21 mL [117, 118]. However, the sip size is much
smaller (9.8 mL ± 6.0) in patients with neurogenic oro-
pharyngeal dysphagia [91]. Increasing the liquid bolus
volume has been shown to increase the risk of aspiration
(Table 4). Interestingly, too small a volume can also be a
problem for dysphagia patients to swallow (Table 4) [102].
This is likely due to the reduced sensory awareness in these
patients and because increased bolus volume increases the
sensory input into the nervous system.
4.4 Administration Devices
The device used to administer an oral liquid is critical in
ensuring that the dose administered is accurate. There are
Table 4 continued
Study population Outcome measures Summary of outcomes References
Dysphagia patients
with dementia or
Parkinson’s disease
Oesophageal transit Both honey-thick and nectar-thick liquids were able to significantly
reduce the risk of aspiration in dysphagia patients compared with thin
liquids
[101]
Volume
Healthy older adults
(aged 61–70 years)
PAS score Increasing the liquid bolus volume increased the risk of aspiration. The
PAS score increased significantly with a 20 mL bolus volume compared
with 5, 10 and 15 mL volumes
[83]
Healthy male adults Oral and pharyngeal phases
of swallowing
Higher liquid bolus volumes (2–20 mL) increased difficulty in
swallowing, including a longer oral retention time and increased
magnitude of structural movement for oropharyngeal clearance
[97]
Patients with
neurogenic dysphagia
Ease of swallowing A liquid volume of 1 mL was more difficult to swallow by stroke patients
than 5 mL volume
[102]
Administration devices
Healthy older adults
(aged 61–70 years)
PAS score No difference in PAS scores between cup and straw drinking [83]
Older patients with
neurogenic dysphagia
PAS score Drinking from a teaspoon resulted in significantly lower PAS scores than
cup drinking
[91]
Patient posture
Patients with
oropharyngeal
dysphagia; head and
neck surgical patients
Prevention of aspiration Head or body postural changes (chin down, chin up, head rotated, head
tilted and lying down) eliminated aspiration in 77 % of patients with
oropharyngeal dysphagia and 60 % patients who had head and neck
surgery
[103, 104]
Dysphagia patients Prevention of aspiration Chin down posture was effective to prevent 55–64 % of aspiration [105, 106]
Dysphagia patients Prevention of aspiration Head rotation was useful in 29 % of patients to prevent aspiration [105]
Healthy adults Pharyngeal clearance Head rotation reduced the UES resting pressure and prolongs the UES
opening, and thus improved pharyngeal clearance during swallowing
[107]
PAS Penetration-Aspiration Scale, UES upper oesophageal sphincter
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Table 5 Acceptability studies of oral flexible formulations in children and older adults
Study population Summary of outcomes References
Multiparticulates
Children (aged
5–16 years)
In the crossover study comparing a valproate sprinkle formulation with syrup, 9 of 12
parents preferred sprinkles due to their ease of use, while 9 children preferred them
due to enhanced palatability, despite the authors reporting a gritty texture
[13]
Children (aged
3–14 years)
Neutral-tasting sodium valproate microgranules were well-accepted and adhered to
over 90 days of treatment, although one-fifth of parents reported difficulty
administering the drug to their child due to the consistency or mouthfeel of the drug
[126]
Children (from 6 months
old)
Microencapsulated iron sprinkles and other micronutrient powders were superior in
terms of ease of use, acceptance and adherence compared with other forms such as
drops and crushable tablets
[127–130]
Infants (5–7 months) Adherence to ferrous fumarate sprinkles was slightly poorer than for drops, with some
parents expressing concerns about the new product and its safety
[131]
Adults and older adults
(mean age 66 years, range
34–83 years)
The majority of patients (67 %) preferred chewable tablets compared with sachet for
calcium and vitamin D supplements. Sachet was considered to be more time-
consuming and more difficult to take than chewable tablets
[132, 133]
Children and adults with
phenylketonuria (aged
8–49 years)
11 of 12 participants preferred a ‘ready to drink’ liquid protein substitute formulation
over powder. The liquid formulation was considered easy to take and more
convenient to use in different environments than the powder
[132, 133]
Dispersible and effervescent tablets
Infants and children (aged
3 months to 5 years)
90 % of caregivers reported that zinc dispersible tablets were as acceptable to their
children, or more so, as other medicines, while 84 % were willing to use the
medicine again in the future
[134]
Children (aged 0–5 years) Acceptability and adherence to diarrhoea treatment was more favourable using zinc
dispersible tablets. Almost 90 % of children received 10 days’ treatment and two-
thirds completed the full 14 days, while only 6.5 % of caregivers reported
administration problems (4 % reported vomiting and 2.5 % refusal to take)
[135]
Children (aged 4–8 years) A citrus-flavoured effervescent tablet was preferred over peppermint-flavoured syrup
by more than two-thirds of the children and their caregivers
[136]
Parkinson’s disease
patients with dysphagia
The acceptability of a dispersible tablet containing levodopa-benserazide was
considered advantageous with regard to ease of administration
[137]
ODTs
Children (aged
6–11 years)
More than 90 % of the children preferred strawberry-flavoured lansoprazole ODTs
over peppermint-flavoured ranitidine syrup
[138]
Children (aged
5–11 years)
The taste of the ondansetron ODTs scored lower than placebo; however, none of the
children rejected or spat out the tablet and 87 % were reportedly willing to take it
again in the future
[139]
Children (aged 6 months
to 10 years)
A randomised clinical trial involved administration of ondansetron ODTs or placebo
to children; however, patient acceptability was not assessed as part of the study
[140]
Adult patients with
depression
More than 80 % of patients preferred ODTs over conventional tablets [141, 142]
Older patients with
schizophrenia
Olanzapine ODTs have been shown to improve medication compliance in acutely ill
non-compliant patients in nursing homes
[143]
Depressed patients older
than 85 years
Mirtazapine ODTs were used for the treatment of depression in these ‘old–old’
patients, and were found to be acceptable and well-tolerated
[144]
Older patients with
Parkinson’s disease
In a multicentre, open-label study, more than twice as many patients preferred
carbidopa–levodopa ODTs (45 %) compared with conventional tablets (20 %)
[145]
Chewable tablets
Children from the age of
2 years
The review summarised chewable tablets to be safe and well-tolerated in children
from this age
[146]
Children (aged
6–11 years)
82 % of the children and 87 % of their parents preferred a cherry-flavoured chewable
montelukast tablet over inhaled therapy, and this formulation resulted in better self-
reported adherence
[147]
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many alternatives available for the delivery of oral liquids
including oral syringes, measuring spoons and measuring
cups. In general, drinking from a spoon is considered safer
for patients with dysphagia than cup and straw drinking
(Table 4). The front edge of the bolus was reported to be
frequently in the hypopharynx before the initiation of the
swallowing during straw drinking and this distal bolus
location was associated with greater occurrences of airway
penetration in dysphagia patients [119].
4.5 Packaging and Storage
Preservatives are required in multidose oral preparations;
however, preservatives are often associated with bitterness
and this needs to be balanced with the overall palatability of
the medicine. The safety and toxicity of the preservatives
used need careful consideration, particularly for neonates.
Packaging liquid medicines in a single-use sachet has ben-
efits in terms of reducing the requirement for preservatives
and also increasing the portability of a medicine. This
packaging is used within the UK for paracetamol suspen-
sions and Gaviscon products. Anecdotal evidence suggest
that carers prefer sachets of certain drugs due to the porta-
bility and also eliminating the need for an additional mea-
suring device as the medicine can be transferred directly
from the sachet to the patient’s mouth. Oral liquids may
require refrigeration, which is a further hurdle for patients
who may require frequent administration of a liquid.
4.6 Patient Posture
Postural changes of the head and body have been frequently
used as compensatory treatments for oropharyngeal dys-
phagia, especially for eliminating aspiration of thin liquids.
The most effective postural techniques include head rota-
tion and chin-down posture—touching the chin to the front
of the neck (Table 4) [105, 106, 120, 121]. The effective-
ness of the chin-down posture in reducing the risk of aspi-
ration is related to a significant narrowing of the laryngeal
entrance and a posterior shift of the epiglottis, and thus
providing a more effective protection of the airway entrance
[122–124]. This technique was seen to be most helpful in
the oldest patients (ages 80–95 years), probably relating to
the changes in the natural neck posture with age [101]. Head
rotation was shown to lateralise the bolus away from the
direction of the head turn during swallowing [107, 125].
This technique is therefore useful for patients with unilat-
eral neurologic or structural damage to the pharynx, by
bypassing the damaged area and improving the efficiency of
swallow. The effect of posture in the very young has not
been examined with respect to medicines administration but
may be of significant importance for babies and infants who
often feed in a horizontal position.
5 Acceptability of Other Flexible Oral Solid Dosage
Forms
Alternatives to liquid medicines are often sought where
liquid medicines are not acceptable to patients; for
example, where taste issues cannot be overcome, more
sophisticated formulation approaches such as encapsula-
tion of drug particles may be required. Many disadvan-
tages associated with taking oral liquids can be avoided
by the use of flexible oral solid medicines that are con-
venient to use by patients who cannot swallow tablets
and capsules. Table 5 describes studies investigating the
acceptability of these formulations in children and older
adults and Table 6 summarises the advantages and
challenges of using these formulations in these patient
groups.
5.1 Multiparticulate Dosage Forms
Multiparticulates include powders, granules and pellets
and are usually presented in sachets or capsules that can
be reconstituted in a drink to provide solutions or sus-
pensions, or applied onto food as ‘sprinkles’. They can
also be further processed to produce other solid formu-
lations including conventional, orally disintegrating or
chewable tablets. Based on recent US FDA guidance,
multiparticulates that are labelled for administration via
sprinkling should have a target size of 2.5 mm, with no
more than 10 % variation over this to a maximum size of
2.8 mm [160]. These formulations are typically consid-
ered as paediatric formulations; however, older patients
can also benefit from their use, such as for the treatment
of Parkinson’s disease, osteoporosis and phenylketonuria
[132, 133, 161].
5.2 Dispersible, Soluble and Effervescent Tablets
Dispersible, soluble and effervescent tablets are solid
dosage forms that can be dispersed or dissolved in a liquid
to form a solution or suspension. These dosage forms
require effective taste masking, as reviewed in Sect. 4.1
relating to oral liquid medicines. These dosage forms are
beneficial in the delivery of large doses of active drug
substances as they are easier to swallow than large tablets.
The acceptability and safety of using dispersible and sol-
uble tablets in older adults, especially those with dyspha-
gia, have not been fully studied. However, effervescent
formulations may be a useful technology to promote safe
swallowing in older patients due to the production of car-
bon dioxide in water. Carbonated water has been found to
be able to improve swallowing in dysphagia patients by
exciting chemical stimulation in the oral cavity (Table 4)
[88, 93, 153]. A national survey in the UK showed that
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Table 6 Advantages and challenges of using flexible oral solid formulations in children and older adults
Advantages Challenges
Multiparticulates
1. Infants can start to swallow thick, semi-solid foods from the age of
6 months and administration of multiparticulates mixed with semi-
solid food is considered appropriate for children above this age
[17]
1. Grittiness and poor mouth feel [13, 16, 126]
2. Lack of knowledge and experience in the use and safety of this
formulation amongst parents and carers [13, 16, 126]
3. Multiparticulates are considered to be more time-consuming and
more difficult to take than liquid formulations and chewable tablets
due to the requirement of handling (mixing with food and drink)
before administration [132, 133]. This could pose challenges to
children and older adults, many of whom rely on caregivers for
taking their medicines
2. Multiparticulates can be mixed with semi-solid food for
administration to older patients. Swallowing is considered safer
with a lower risk of aspiration in dysphagia patients when semi-
solid food, such as paste, pudding and rice is swallowed than with
liquids [148–150]
Dispersible and effervescent tablets
1. These tablets are potentially suitable to be administered to infants
under 6 months of age for drug substances and excipients that are
compatible with breast milk [151]. A ‘nipple shield delivery
system’ (NSDS) could facilitate this novel method of infant drug
delivery [152]
1. These formulations usually require the application of a large volume
of water, which could be problematic for both children and older
patients who find swallowing a large amount of liquid difficult,
especially in patients with dysphagia [70]
2. The risk of aspiration in dysphagia patients for swallowing thin
liquids resulted from these formulations would need to be
considered
3. Effervescent formulations showed high capacity for tooth erosion,
even more so than sugar-containing medicines, which should be
considered for long-term use in children and older people [154]
4. Soluble and dispersible formulations often contain a high quantity of
sodium and the maximum daily dose of these medications could
exceed the recommended daily dietary intake of sodium [155].
Prescribing sodium-containing formulations was associated with
increased cardiovascular incidents [155] and the use of effervescent
formulations was responsible for poor blood pressure control in
older hypertension patients [156]
2. Carbonated water generated by effervescent formulations could
potentially improve safe swallowing in dysphagia patients [88, 93,
153]
ODTs
1. ODTs are generally acceptable in children and older patients,
which is normally associated with their taste, texture, ease of use
and reduced concern about difficulties in swallowing [141, 142,
145]
1. The risk of aspiration remains the same in swallowing ODTs as
conventional tablets in dysphagia patients [157]
2. ODTs are easier to swallow than conventional tablets in dysphagia
patients [157]. Fewer numbers of swallows, shorter swallowing
duration, reduced muscular effort and less fluid assistance are
required in swallowing ODTs than conventional tablets
3. The use of ODTs can be beneficial for patients who are purposely
non-adherent, particularly in relation to antipsychotic treatments,
as it is more difficult to spit the tablet out or hide the formulation in
the mouth [158]
4. The ease of administration of ODTs can be advantageous to reduce
the work burden on nursing staff and caregivers who assist the
administration of medicines in older patients [143]
Chewable tablets
1. Many chewable formulations are licensed for use in children from
the age of 2 years and were found to be safe and well-tolerated in
children from this age [146, 147]
1. Chewable tablets have the potential for tooth erosion over long-term
use [154]
2. Use in older patients could be limited due to the decline in chewing
ability
3. Adverse events are associated with the swallowing of intact or
partially chewed chewable tablets, such as intestinal obstruction,
ischaemia and perforation [159]. The issue can be augmented by the
large variation in chewability of commercially available chewable
tablets [159]
ODTs orally disintegrating tablets
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90 % of the prescribed and issued over-the-counter ‘easy to
swallow’ solid formulations were effervescent tablets for
long-term use in older people [162].
5.3 Orally Disintegrating Formulations
Orally disintegrating formulations include tablets, films
and thin wafers. These formulations are relatively new
innovations in improving patient compliance and accep-
tance, especially for paediatric and geriatric patients. These
preparations may be applicable for use across the paediatric
population, including infants and young children; however,
evidence of their use and acceptability in these subsets is
lacking. A number of orally disintegrating tablet and film
formulations have been developed for the treatment of
diseases that are common in the older population such as
pain, depression, Parkinson’s disease and Alzheimer’s
disease [163, 164].
5.4 Chewable Tablets
Chewable tablets are another dosage form useful for
paediatric and geriatric patients who are unable to
swallow conventionally sized monolithic dosage forms
intact. In typically developing children, deciduous (pri-
mary) teeth begin to erupt from 6 months of age and the
complete set of 20 have usually erupted between the ages
of 2 and 3 years. Exfoliation of deciduous teeth begins
from 6 to 7 years of age, with complete replacement by
permanent teeth usually completed by the age of
12–13 years. Recent research suggests continual refine-
ment of chewing skills occurs until at least the age of
3 years, at which time chewing patterns and efficiency
also stabilise [165].
Despite the recent popularity of chewable tablets in
children, their usage in older adults may be limited due to
the deteriorations of chewing ability in this age group.
The prevalence of chewing problems was observed to be
40 % among older Tanzanian citizens (aged
50–100 years) [166]. In Finland, chewing ability was
considered poor in 55 % of long-term hospitalised older
individuals and 65 % could eat mashed food only [167].
The loss of teeth is regarded as the primary factor
accounting for the deterioration of the chewing ability and
the possession of more than 20 teeth is essential for
retaining good chewing capacity. However, a survey in
Japan showed that 65 % of older people (aged
75–100 years) had less than 20 teeth [168]. In Denmark,
half of the 75- and 85-year-old men and women in a
suburban area were edentulous and only 15 % still had
more than 20 teeth [169]. As a result, chewing problems
were shown in three-quarters of those very old men and
women who have lost all of their natural teeth.
5.5 Films and Jellys
A film formulation provides easy swallow through the
application of a dry film that turns into a jelly instanta-
neously in the mouth by absorbing a small amount of saliva
[170]. The film consists of an inner layer that contains the
active drug and two gelling layers covering the drug layer
(Fig. 1). The dissolution of the drug in the mouth was
limited by the gel layer which swells by absorbing water
(Fig. 2). The oesophageal transit of the film was signifi-
cantly quicker than gelatin capsules [170]. The technology
may be difficult to use in older people with xerostomia,
which is a common symptom in the older population,
particularly related to the increased use of medications
[171]. A drug-containing oral jelly was developed to
improve swallowing for older patients [172]. The formu-
lation comprises a jelly portion and an air portion which
can be pushed to extrude the jelly when opening the
package.
6 Acceptability of Dosage Forms Designed
for Particular Therapeutic Effects
6.1 Modified-Release Formulations
Oral modified-release formulations enable longer and more
patient-friendly dosing intervals. This can be beneficial in
children to avoid the need to take medicines at school or
nursery settings and to improve adherence in older patients.
More simplified dose regimens with fewer daily doses have
been associated with higher patient adherence [10]. It was
found that patient adherence was significantly higher with
once- and twice-daily regimens than three and four times
daily regimens. Further evidence shows that adherence can
be improved by switching from twice-daily to once-daily
therapy [173]. Adherence to antiretroviral therapy was
significantly improved when patients were switched from
twice-daily to once-daily stavudine treatments for HIV
[174]. However, for extended-release formulations,
Fig. 1 Schematic structure of the easy-swallowing film formulation
(reproduced from Okabe et al. [170], with permission)
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patients need to be reminded that doses should be taken at
approximately equal time intervals, e.g. the same time of
the day for once-daily preparations. Taking doses too far
apart or too close together for these formulations may
result in decreased efficacy or increased adverse effects.
Conventionally, modified-release formulations are
designed as single-unit dosage forms that contain the active
ingredient in a single tablet or capsule. These formulations
are challenging for children and older patients to swallow
(see Sect. 3.1). Crushing modified-release tablets prior to
administration poses an additional risk of toxicity due to
the high level of active drug contents. There have been
reports of patient deaths resulting from administrating
crushed modified-release tablets to older dysphagia
patients [175]. Modified-release multiparticulate systems
offer a more flexible method for administration to children
and older patients and exist as granules, pellets, beads,
mini-tablets, microspheres and microcapsules [176–179].
These multiple-unit modified-release systems can be filled
into capsules/sachets or compressed into orally disinte-
grating tablets as the final dosage form [180, 181].
6.2 Fixed-Dose Combinations
Fixed-dose combinations could be useful to reduce pill
burden in older patients and could be beneficial for pae-
diatric patients with combined drug therapies such as
treatment for HIV. However, this could increase the size of
the tablet and cause further swallowing issues. A potential
solution could be different coloured pellets that could be
mixed together at different strengths by the manufacturer
or pharmacist. Fixed-dose combinations in the forms of
oral suspensions and dispersible tablets have been proposed
in paediatrics for the treatment of HIV [182]. Kayitare et al.
[183] have developed a fixed-dose combination tablet of
zidovudine and lamivudine for paediatric use that allows
dose flexibility and easy administration to children. The
rectangular tablet can be broken into eight subunits for
dose adjustment according to body weight and each subunit
disintegrates rapidly in a small volume of liquid to aid
administration. It was suggested that the tablet is suitable
for children from infants (from 1 month old) to adolescents
(up to 18 years of age) [183].
7 Concluding Remarks
Children and older adults share similarities in oral medi-
cation acceptability, particularly difficulties in swallowing
conventional tablets and capsules. Appropriate formulation
design and selection affect the acceptability of medicines in
these two age groups and have an impact on patient safety,
therapeutic outcomes and adherence. However, distinct
differences in relation to drug therapy are notable in chil-
dren and older people, and separate considerations in pre-
scribing and formulation development should be given to
the two populations. Whilst taste, smell and palatability are
major concerns in developing paediatric formulations,
characteristics of a medicine affecting safe swallowing are
of significant importance in older patients, especially to
prevent oesophageal retention and risk of aspiration.
Nevertheless, both the young and older populations benefit
Fig. 2 The swelling behaviour
of the film formulation in
purified water (reproduced from
Okabe et al. [170], with
permission)
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enormously from the advances in pharmaceutical technol-
ogy which offers bespoke and appropriate formulations of
choice to meet their needs.
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